
The pharmaceutical industry is driving the next drug revolution with AI and biotech innovations. Companies are using automation to streamline processes, boosting productivity and accuracy. Investors favor the sector for its steady profits, resilience during economic shifts, and sustained demand, driven by factors such as rising chronic illnesses.
Amid this favorable backdrop, investors could consider buying fundamentally strong pharmaceutical stocks: AbbVie Inc. (ABBV), Bristol-Myers Squibb Company (BMY), and Gilead Sciences, Inc. (GILD).